Last reviewed · How we verify

NCT07520305

Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes

Not yet recruiting NA Last updated 9 April 2026
What this trial tests

NA trial testing Lactobacillus paracasei LC19 Intervention in Type 2 Diabetes in 70 participants. Not yet recruiting.

Timeline
20 April 2026
Primary endpoint
31 December 2027
31 March 2028

Quick facts

Lead sponsorBeijing Chao Yang Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment70
Start date20 April 2026
Primary completion31 December 2027
Estimated completion31 March 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Chao Yang Hospital

Who can join

Adults 18 to 65, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm study to investigate the heterogeneity of glycemic response to Lactobacillus paracasei LC19 in patients with newly diagnosed type 2 diabetes. Participants will receive LC19 for 12 weeks, and changes in glycemic control will be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Beijing Chao Yang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07520305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing